# Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

> **NCT05776940** · PHASE3 · UNKNOWN · sponsor: **Air Force Military Medical University, China** · enrollment: 116 (estimated)

## Conditions studied

- Immunoglobulin Light-chain Amyloidosis

## Interventions

- **DRUG:** Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
- **DRUG:** Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab

## Key facts

- **NCT ID:** NCT05776940
- **Lead sponsor:** Air Force Military Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-31
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776940, "Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05776940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*